LGND · Ligand Pharmaceuticals Inc · Documents
$322.75
+5.42 (+1.71%)
At close · Oct 30
Return incl. dividend (before tax)
Q3 2026 earnings call transcript
Market Cap
$6.43B
Shares
20.00M
Volume · Oct 30
344.37K
Avg daily vol (3M)
241.18K
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | AI summary | Filing Date | Period | Open |
|---|---|---|---|---|
| 10-Q | After acquiring XOMA Royalty on July 14, 2026, Ligand's portfolio exceeded 200 assets. Q3 2026 royalties rose 51% to $70.3 million, but revenue and income fell 32% to $78.7 million; cash and investments totaled $447.4 million at September 30, 2026. | 2026-10-30 | 2026-09-30 | |
| 8-K | — | 2026-10-29 | — | |
| 8-K | Ligand Pharmaceuticals Incorporated entered a financing agreement with AvenCell Therapeutics, Inc. for up to $47 million, including up to $41 million for royalties on AvenCell assets and up to $6 million in Series C financing. | 2026-09-24 | — | |
| 8-K | Ligand acquired royalty and milestone rights to Santen’s Ryjunea from Sydnexis for $23 million upfront, including a tiered low-double-digit to high-teens royalty on net sales in EMEA and certain milestone payments. | 2026-09-22 | — | |
| 8-K/A | — | 2026-09-02 | 2026-07-14 | |
| 10-Q | — | 2026-08-07 | 2026-06-30 | |
| 8-K | — | 2026-08-06 | — | |
| 8-K | — | 2026-07-14 | — | |
| 8-K | — | 2026-06-25 | — | |
| 8-K | — | 2026-06-22 | — | |
| 8-K | — | 2026-06-09 | 2026-06-05 | |
| DEFA14A | — | 2026-05-18 | — | |
| 8-K | — | 2026-05-18 | 2026-05-16 | |
| 10-Q | — | 2026-05-08 | 2026-03-31 | |
| 8-K | — | 2026-05-07 | — | |
| 8-K | — | 2026-04-30 | 2026-04-24 | |
| DEFA14A | — | 2026-04-28 | — | |
| DEFA14A | — | 2026-04-27 | — | |
| 8-K | — | 2026-04-27 | — | |
| DEF 14A | — | 2026-04-21 | 2025-12-31 | |
| ARS | — | 2026-04-21 | 2025-12-31 | |
| DEFA14A | — | 2026-04-21 | — | |
| 10-K | — | 2026-02-27 | 2025-12-31 | |
| S-3ASR | — | 2026-02-27 | — | |
| 8-K | — | 2026-02-26 | — | |
| 8-K | — | 2025-12-18 | — | |
| 10-Q | — | 2025-11-07 | 2025-09-30 | |
| 8-K | — | 2025-11-06 | — | |
| 8-K | — | 2025-09-16 | 2025-09-12 | |
| 8-K | — | 2025-08-14 | 2025-08-11 | |
| 8-K | — | 2025-08-11 | — | |
| 10-Q | — | 2025-08-08 | 2025-06-30 | |
| 8-K | — | 2025-08-07 | — | |
| 8-K | — | 2025-07-02 | — | |
| 8-K | — | 2025-06-09 | — | |
| 10-Q | — | 2025-05-09 | 2025-03-31 | |
| 8-K | — | 2025-05-08 | — | |
| DEF 14A | — | 2025-04-22 | 2024-12-31 | |
| DEFA14A | — | 2025-04-22 | — | |
| ARS | — | 2025-04-22 | 2024-12-31 | |
| 8-K | — | 2025-04-17 | 2025-04-16 | |
| 10-K | — | 2025-02-28 | 2024-12-31 | |
| 8-K | — | 2025-02-27 | — | |
| 8-K | — | 2025-02-25 | 2025-02-24 | |
| 10-Q | — | 2024-11-08 | 2024-09-30 | |
| 8-K | — | 2024-11-07 | — | |
| 10-Q | — | 2024-08-07 | 2024-06-30 | |
| 8-K | — | 2024-08-06 | — | |
| 8-K | — | 2024-08-02 | — | |
| 8-K | — | 2024-07-17 | 2024-07-15 |
Showing 1–50 of 163 filings
Key facts
CIK
886163
CUSIP
53220K504
13F (30d)
134 filings
125 filers
Visit website
Investor relations